You searched for: overlevelsesfordel (Danska - Engelska)

der var dog ingen overlevelsesfordel for patienter med fremskreden pancreascancer, som ikke havde spredt sig til andre organer end pancreas.
however, there was no survival advantage for patients with advanced pancreatic cancer that had not spread beyond the pancreas.

der blev også vist overlevelsesfordel hos patienter, der ikke havde opnået et fuldstændigt respons, for vidaza, sammenlignet med ccr.
a survival benefit was also demonstrated in patients that had not achieved a complete response for vidaza compared to ccr.

en overlevelsesfordel blev ligeledes påvist hos patienter, som ikke havde opnået et komplet/partielt respons efter behandling med azacitidin.
a survival benefit was also demonstrated in patients that had not achieved a complete/partial response following azacitidine treatment.

brugen af defitelio som rescue- behandling til alle patienter, der fik vod, indebar, at undersøgelsens design ikke gav mulighed for at vurdere en overlevelsesfordel, som undersøgelsen da heller ikke viste.
the use of defitelio rescue treatment for all patients who developed vod meant that the study was not designed to assess any survival advantage and none was seen in this study.

den samlede langtidsoverlevelse blev evalueret med 5 års opfølgning efter efs-analysen og viste fortsat en overlevelsesfordel for patienter, der fik dinutuximab-immunterapi, sammenlignet med dem, der fik isotretinoin alene.
long-term overall survival was evaluated with 5 years of follow up after the efs analysis and continued to demonstrate a survival advantage for patients who received dinutuximab immunotherapy compared to those who received isotretinoin alone.

selvom 170 ud af 351 patienter, som blev randomiseret til placebo/ dexamethason, modtog behandling med lenalidomid/ dexamethason, efter at studierne var blevet afblindet, viste den poolede analyse af den samlede overlevelse (os) en statistisk væsentlig overlevelsesfordel for lenalidomid/ dexamethason sammenlignet med placebo/ dexamethason (hazard ratio = 0, 75, 95% konfidensinterval = [0, 59; 0, 95], p = 0, 015).
despite the fact that 170 out of the 351 patients randomised to placebo/dexamethasone received treatment with lenalidomide/dexamethasone after the studies were unblinded, the pooled analysis of os demonstrated a statistically significant survival advantage for lenalidomide/dexamethasone relative to placebo/dexamethasone (hazard ratio = 0.75, 95% ci = [0.59, 0.95], p=0.015).